0001564590-21-037686.txt : 20210723 0001564590-21-037686.hdr.sgml : 20210723 20210723091702 ACCESSION NUMBER: 0001564590-21-037686 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210722 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210723 DATE AS OF CHANGE: 20210723 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACORDA THERAPEUTICS INC CENTRAL INDEX KEY: 0001008848 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31938 FILM NUMBER: 211109234 BUSINESS ADDRESS: STREET 1: 420 SAW MILL RIVER ROAD CITY: ARDSLEY STATE: NY ZIP: 10502 BUSINESS PHONE: 914-347-4300 MAIL ADDRESS: STREET 1: 420 SAW MILL RIVER ROAD CITY: ARDSLEY STATE: NY ZIP: 10502 8-K 1 acor-8k_20210722.htm ACOR_8K_07202021 acor-8k_20210722.htm
false 0001008848 0001008848 2021-07-22 2021-07-22

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 22, 2021

 

Acorda Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-31938

13-3831168

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

420 Saw Mill River Road,

Ardsley, NY

 

10502

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (914) 347-4300

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock (Par Value $0.001)

 

ACOR

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 8.01. Other Events.

 

On July 22, 2021, Acorda Therapeutics, Inc. (the “Company”) issued a press release announcing that it has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A to commercialize INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Spain. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated by reference into this Item 8.01.

 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

 

Description

99.1

 

Press Release dated July 22, 2021

104

 

Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

 


 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Acorda Therapeutics, Inc.

 

 

 

July 23, 2021

By:

/s/ Robert Morales

 

 

Name: Robert Morales

 

 

Title: Vice President, Finance and Controller

and interim principal financial and accounting officer

 

 

 EX-99.1 2 acor-ex991_6.htm PRESS RELEASE acor-ex991_6.htm

EXHIBIT 99.1

 

CONTACT:

Tierney Saccavino

(914) 326-5104

tsaccavino@acorda.com

 

FOR IMMEDIATE RELEASE

 

Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain

 

ARDSLEY, N.Y. – July 22, 2021 – Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A (ESTEVE) to commercialize INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) in Spain. INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibitor. (1)

 

Under the terms of the supply agreement, ACORDA will receive a significant double-digit percent of the selling price of INBRIJA in Spain in exchange for supply of the product. ESTEVE will have the exclusive distribution rights to INBRIJA in the territory and ACORDA will supply the product to ESTEVE. ESTEVE expects to launch INBRIJA in Spain in the fourth quarter of 2022.

 

According to current population estimates, there are at least 300,000 people living with Parkinson's disease in Spain, and there is one new case per 10,000 people per year; these incidence and prevalence rates are similar to those in the rest of Europe.(2)

 

“We are delighted to enter a partnership with ESTEVE to make INBRIJA available in Spain. This is great news for people with Parkinson’s in Spain who are in need of therapies to treat their OFF periods. ESTEVE has an impressive track record of successfully commercializing pharmaceuticals in Europe for neurological and other indications,” said Ron Cohen, M.D., President and CEO of Acorda Therapeutics. “We are also in active discussions with additional companies for the rights to INBRIJA in other countries in Europe and the rest of the world.”

 

About Acorda Therapeutics

Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

 

Forward-Looking Statements

 

This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including: we may not be able to successfully market AMPYRA, INBRIJA or any other products under development; the COVID-19 pandemic, including related quarantines and travel restrictions, and the potential for the illness to affect our employees or consultants or those that work for other companies we rely

1. https://www.ema.europa.eu/en/documents/product-information/inbrija-epar-product-information_en.pdf.

2. The social impact of Parkinson's disease in Spain: Report by the Spanish Foundation for the Brain. R. García-Ramos. 2016, Neurología, págs. 401—413.

 

upon, could have a material adverse effect on our business operations or product sales; our ability to raise

additional funds to finance our operations, repay outstanding indebtedness or satisfy other obligations, and our ability to control our costs or reduce planned expenditures; risks associated with the trading of our common stock and our reverse stock split; risks related to our workforce, including our ability to realize the expected benefits of our corporate restructuring; risks associated with complex, regulated manufacturing processes for pharmaceuticals, which could affect whether we have sufficient commercial supply of INBRIJA to meet market demand; our reliance on third-party manufacturers for the production of commercial supplies of AMPYRA and INBRIJA; third-party payers (including governmental agencies) may not reimburse for the use of INBRIJA at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; reliance on collaborators and distributors to commercialize INBRIJA and AMPYRA outside the U.S.; competition for INBRIJA and AMPYRA, including increasing competition and accompanying loss of revenues in the U.S. from generic versions of AMPYRA (dalfampridine) following our loss of patent exclusivity; the ability to realize the benefits anticipated from acquisitions, among other reasons because acquired development programs are generally subject to all the risks inherent in the drug development process and our knowledge of the risks specifically relevant to acquired programs generally improves over time; the risk of unfavorable results from future studies of INBRIJA (levodopa inhalation powder) or from other research and development programs, or any other acquired or in-licensed programs; the occurrence of adverse safety events with our products; the outcome (by judgment or settlement) and costs of legal, administrative or regulatory proceedings, investigations or inspections, including, without limitation, collective, representative or class-action litigation; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third-party intellectual property licenses needed for the commercialization of our products; and failure to comply with regulatory requirements could result in adverse action by regulatory agencies.

 

These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this press release are made only as of the date hereof, and we disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

 

###

 

 

 GRAPHIC 3 gbnaaoin0l2g000001.jpg GRAPHIC begin 644 gbnaaoin0l2g000001.jpg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acor-20210722.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 acor-20210722_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of each class Security12b Title Trading Symbol Trading Symbol Name of each exchange on which registered Security Exchange Name EX-101.PRE 6 acor-20210722_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 acor-8k_20210722_htm.xml IDEA: XBRL DOCUMENT 0001008848 2021-07-22 2021-07-22 false 0001008848 8-K 2021-07-22 Acorda Therapeutics, Inc. DE 001-31938 13-3831168 420 Saw Mill River Road Ardsley NY 10502 (914) 347-4300 false false false false Common Stock (Par Value $0.001) ACOR NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Jul. 22, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 22, 2021
Entity Registrant Name Acorda Therapeutics, Inc.
Entity Central Index Key 0001008848
Entity Emerging Growth Company false
Entity File Number 001-31938
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 13-3831168
Entity Address, Address Line One 420 Saw Mill River Road
Entity Address, City or Town Ardsley
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10502
City Area Code (914)
Local Phone Number 347-4300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of each class Common Stock (Par Value $0.001)
Trading Symbol ACOR
Name of each exchange on which registered NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports acor-8k_20210722.htm acor-20210722.xsd acor-20210722_lab.xml acor-20210722_pre.xml acor-ex991_6.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "acor-8k_20210722.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "acor-8k_20210722.htm" ] }, "labelLink": { "local": [ "acor-20210722_lab.xml" ] }, "presentationLink": { "local": [ "acor-20210722_pre.xml" ] }, "schema": { "local": [ "acor-20210722.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "acor", "nsuri": "http://www.acorda.com/20210722", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "acor-8k_20210722.htm", "contextRef": "C_0001008848_20210722_20210722", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "acor-8k_20210722.htm", "contextRef": "C_0001008848_20210722_20210722", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of each exchange on which registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.acorda.com/20210722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-21-037686-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-037686-xbrl.zip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end